RCKT 10-DAY DEADLINE ALERT: FDA Clinical Hold on RP-A501 Trial Triggers Rocket Pharmaceuticals (RCKT) Stock Plunge and Class Action – Hagens Berman

Core Viewpoint - Rocket Pharmaceuticals faced a significant decline in stock value after the FDA placed a clinical hold on its Phase 2 trial for RP-A501, leading to a 62% drop in share price on May 27, 2025, following the announcement of a patient's serious adverse event and subsequent death [1][9]. Group 1: Company Overview - Rocket Pharmaceuticals is a biotechnology company focused on developing gene therapies for rare diseases, specifically targeting Danon disease [4]. - The company had previously communicated strong progress in its gene therapy development, citing positive Phase 1 results as evidence of safety and efficacy [7]. Group 2: Legal Proceedings - A securities class action lawsuit has been filed against Rocket Pharmaceuticals, alleging that the company misled investors regarding the safety and progress of the RP-A501 trial [2][4]. - The lawsuit covers shareholders who purchased Rocket stock between February 27, 2025, and May 26, 2025, focusing on whether the company provided materially false and misleading statements about the trial [5]. Group 3: Allegations and Misconduct - Plaintiffs claim that Rocket Pharmaceuticals failed to disclose significant protocol changes and known risks associated with serious adverse events, including patient deaths, despite publicly expressing confidence in the trial's progress [6][8]. - The class action complaint alleges that the company amended the study protocol to introduce a new immunomodulatory agent without informing investors, which contributed to the inflated stock price prior to the FDA's announcement [8][10].